ArticleClinical hypertension2026
Cardiac magnetic resonance assessment of left ventricular phenotypes and prognostic implications in hypertensive heart disease.
Article in Clinical hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Determinants, risk score, and prognostic implications of left ventricular thrombus in ischemic cardiomyopathy assessed by cardiac magnetic resonance: a retrospective cohort study.Annals of medicine · 2026Article
- Hypertensive heart disease and HFpEF:atrial functional valve regurgitation as the trigger of acute heart failure in a syndrome of exertional dyspnoea.Journal of human hypertension · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies have demonstrated an association between left ventricular (LV) phenotypes assessed by echocardiography and clinical outcomes in patients with hypertensive heart disease (HHD). However, data evaluating LV phenotypes using cardiac magnetic resonance (CMR)-the reference standard for quantification of LV volume, mass, and function-remain limited. This study aimed to assess the prognostic value of CMR-derived LV phenotypes in patients with HHD. Methods: We included 756 consecutive patients with hypertension who were referred for clinically indicated CMR at an academic hospital in Thailand between 2011 and 2019. Four LV phenotypes were defined using LV mass index (LVMI), LV mass-to-volume ratio, and LV end-diastolic volume index (LVEDVI). Patients were followed for major adverse cardiovascular events (MACE), defined as a composite of all-cause death, myocardial infarction, hospitalization for heart failure, and stroke. Results: The mean age was 70 ± 10 years, and 47% of patients were male. At baseline, 42.3% had controlled blood pressure, 37.0% had grade 1 hypertension, and 20.7% had grade 2-3 hypertension. The mean LVEF was 70.9 ± 9.7%. Over a median follow-up of 7.1 years (interquartile range 4.1-9.2), 153 MACE occurred. Annualized MACE rates were highest in patients with eccentric hypertrophy (5.8 per 100 patient-years), followed by concentric hypertrophy (3.5), concentric remodeling (2.7), and normal geometry (1.5). After multivariable adjustment, concentric remodeling (adjusted hazard ratio [HR], 2.22; 95% confidence interval [CI], 1.30-3.81; Conclusions: CMR-based LV phenotyping was associated with prognosis in patients with HHD, with abnormal LV phenotypes demonstrating higher risks of MACE compared with normal geometry. These findings indicate that CMR may have a complementary role in risk assessment among patients with hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.